The goal of this clinical trial is to evaluate the visual and anatomical outcomes of large (410-1000 μm) full-thickness macular holes repair surgery using perfluoropropane (15% C3F8), sulfur hexafluoride (20% SF6) gas tamponade.

The project is a randomized clinical trial with a follow up time of 6 months comparing the effects of surgical treatment of large (410-1000 μm) idiopathic macular holes. Patients are randomized to vitrectomy surgery with internal limiting membrane peeling using perfluoropropane (15% C3F8), sulfur hexafluoride (20% SF6) gas tamponad. Intra- and postoperative complications are registered.

Inclusion Criteria:

• Patient age 50 or above.
• Duration of Symptoms ≤ 12 months.
• Macular holes having a diameter 410-1000 μm.
• Informed consent.

Exclusion Criteria:

• Patients under 50 years of age.
• A patient who has already undergone treatment (surgery, laser etc.) for any disease of the retina.
• Traumatic or pediatric macular holes, and associated retinal detachment.
• History of any retinal disease such as high myopia, retinal dystrophies, central serous retinopathy, retinal vascular diseases, diabetic retinopathy, uveitis etc.
• Previous history of glaucoma or ocular hypertension.
• Failure to give informed consent.